Inhibition of the proton pump in the parietal cells has been established as the main therapeutic principle in the treatment of acid-related diseases, such as peptic ulcer and gastro-oesophageal reflux. The proton pump inhi- bitors are tailored for their purpose. They accumulate in the target cell, are activated by acid and bind strongly to the specific target - the proton pump. The clinical superiority of the proton pump inhibitors is due not only to their high efficacy but also to the long duration of the acid inhibition in comparison with other antisecretory drugs. At present when drug discovery mostly relies on identification and characterization of potential targets by genome research, molecular biology, combinatorial chemistry and automated screening, it seems worthwhile to present the development of the tITst proton pump inhibitor - omeprazol- starting from a chemical structure with an observed antisecretory effect but also severe toxic effects that had to be eliminated. As always, basic and applied research operate luind in hand to optimize the delicate balance be- tween efficacy and safety of a new drug. This goal often involves time and many different specialists.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
Etat : New. In. N° de réf. du vendeur ria9783034897778_new
Quantité disponible : Plus de 20 disponibles
Vendeur : Brook Bookstore On Demand, Napoli, NA, Italie
Etat : new. Questo è un articolo print on demand. N° de réf. du vendeur E0DLBYUVFO
Quantité disponible : Plus de 20 disponibles
Vendeur : moluna, Greven, Allemagne
Kartoniert / Broschiert. Etat : New. N° de réf. du vendeur 4319586
Quantité disponible : Plus de 20 disponibles
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Inhibition of the proton pump in the parietal cells has been established as the main therapeutic principle in the treatment of acid-related diseases, such as peptic ulcer and gastro-oesophageal reflux. The proton pump inhi bitors are tailored for their purpose. They accumulate in the target cell, are activated by acid and bind strongly to the specific target - the proton pump. The clinical superiority of the proton pump inhibitors is due not only to their high efficacy but also to the long duration of the acid inhibition in comparison with other antisecretory drugs. At present when drug discovery mostly relies on identification and characterization of potential targets by genome research, molecular biology, combinatorial chemistry and automated screening, it seems worthwhile to present the development of the tITst proton pump inhibitor - omeprazol- starting from a chemical structure with an observed antisecretory effect but also severe toxic effects that had to be eliminated. As always, basic and applied research operate luind in hand to optimize the delicate balance be tween efficacy and safety of a new drug. This goal often involves time and many different specialists. 251 pp. Englisch. N° de réf. du vendeur 9783034897778
Quantité disponible : 2 disponible(s)
Vendeur : Rarewaves.com UK, London, Royaume-Uni
Paperback. Etat : New. Softcover reprint of the original 1st ed. 1999. N° de réf. du vendeur LU-9783034897778
Quantité disponible : Plus de 20 disponibles
Vendeur : preigu, Osnabrück, Allemagne
Taschenbuch. Etat : Neu. Proton Pump Inhibitors | Lars Olbe | Taschenbuch | x | Englisch | 2013 | Birkhäuser | EAN 9783034897778 | Verantwortliche Person für die EU: Springer Basel AG in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu. N° de réf. du vendeur 105646056
Quantité disponible : 5 disponible(s)
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -Inhibition of the proton pump in the parietal cells has been established as the main therapeutic principle in the treatment of acid-related diseases, such as peptic ulcer and gastro-oesophageal reflux. The proton pump inhi bitors are tailored for their purpose. They accumulate in the target cell, are activated by acid and bind strongly to the specific target - the proton pump. The clinical superiority of the proton pump inhibitors is due not only to their high efficacy but also to the long duration of the acid inhibition in comparison with other antisecretory drugs. At present when drug discovery mostly relies on identification and characterization of potential targets by genome research, molecular biology, combinatorial chemistry and automated screening, it seems worthwhile to present the development of the tITst proton pump inhibitor - omeprazol- starting from a chemical structure with an observed antisecretory effect but also severe toxic effects that had to be eliminated. As always, basic and applied research operate luind in hand to optimize the delicate balance be tween efficacy and safety of a new drug. This goal often involves time and many different specialists.Springer Nature c/o IBS, Benzstrasse 21, 48619 Heek 268 pp. Englisch. N° de réf. du vendeur 9783034897778
Quantité disponible : 1 disponible(s)
Vendeur : Books Puddle, New York, NY, Etats-Unis
Etat : New. pp. 268. N° de réf. du vendeur 2698259828
Quantité disponible : 4 disponible(s)
Vendeur : Mispah books, Redhill, SURRE, Royaume-Uni
Paperback. Etat : Like New. Like New. book. N° de réf. du vendeur ERICA79630348977746
Quantité disponible : 1 disponible(s)
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Taschenbuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - Inhibition of the proton pump in the parietal cells has been established as the main therapeutic principle in the treatment of acid-related diseases, such as peptic ulcer and gastro-oesophageal reflux. The proton pump inhi bitors are tailored for their purpose. They accumulate in the target cell, are activated by acid and bind strongly to the specific target - the proton pump. The clinical superiority of the proton pump inhibitors is due not only to their high efficacy but also to the long duration of the acid inhibition in comparison with other antisecretory drugs. At present when drug discovery mostly relies on identification and characterization of potential targets by genome research, molecular biology, combinatorial chemistry and automated screening, it seems worthwhile to present the development of the tITst proton pump inhibitor - omeprazol- starting from a chemical structure with an observed antisecretory effect but also severe toxic effects that had to be eliminated. As always, basic and applied research operate luind in hand to optimize the delicate balance be tween efficacy and safety of a new drug. This goal often involves time and many different specialists. N° de réf. du vendeur 9783034897778
Quantité disponible : 1 disponible(s)